NCT04468958已完成1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of SAB-185 in Healthy Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 6
- 主要终点
- Number of Participants Having Adverse Events
研究概览
简要总结
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in healthy participants.
详细描述
There were 4 treatment groups and 1 control group. Cohort 1 received 1 dose of SAB-185 at 10 mg/kg per dose. Cohort 2 received 1 dose of SAB-185 at 25 mg/kg, Cohort 3 received 2 doses of SAB-185 at 25 mg/kg each 7 days apart, and Cohort 4 received 1 dose of SAB-185 at 50 mg/kg per dose. All the doses were prepared at the site by the pharmacy staff or designee for delivery to the clinical staff for administration, per the site's SOPs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must meet all of the following criteria for inclusion:
- •18-60 years of age
- •Able to understand the study and comply with all study procedures
- •Agrees not to participate in any other trial of an investigational product during the study period
- •Willing and able to provide written informed consent prior to the start of any study related activities
- •In good health in the opinion of the site principal investigator as determined by vital signs, medical history, physical examination and clinical laboratory tests
- •If female, meets at least one of the following reproductive risk criteria
- •Post-menopausal for at least 12 months
- •Use of one or more of the following highly effective contraceptive methods for at least 90 days following the last dose of study product: combined estrogen and progestogen containing or progestogen-only hormonal contraception, intrauterine device (IUD), intrauterine hormone-releasing system, surgical bilateral tubal occlusion
- •Vasectomized sole sexual partner who has received medical assessment of the surgical success
- •Subjects agree to sexual abstinence (refraining from heterosexual intercourse for at least 90 days following the last dose of study product) if not using birth control or condoms for males.
排除标准
- •Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period.
- •Treatment or participation in another clinical trial of any other investigational agent within 30 days prior to enrollment.
- •Use of other drugs that, in the opinion of the investigator, could complicate analysis of SAB-
- •Subjects with the following risk factors:
- •Compromised immune system including confirmed diagnosis of current cancer under treatment, inherited deficiencies of the immune system, immune suppressing medication, or other conditions causing leukopenia or neutropenia
- •Known autoimmune condition requiring therapy more intensive than intermittent non-steroidal anti-inflammatories in the prior 6 months (for example: rheumatoid arthritis, lupus, inflammatory bowel disease)
- •Chronic respiratory disease including COPD, emphysema, cystic fibrosis, pulmonary hypertension, or other chronic condition that requires the routine use of supplemental oxygen
- •Chronic asthma requiring the use of oral steroids or hospitalization in the last six months
- •Renal failure or renal insufficiency requiring dialysis
- •Congestive heart failure or significant atherosclerotic disease (coronary artery disease or peripheral vascular disease)
- •Hypertension, diabetes, those currently vaping or smoking or with a history of chronic smoking, and those with BMI > 35 kg/m2
- •Receipt of pooled immunoglobulin or plasma in past 30 days
- •Any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of SAB-185
- •Known IgA deficiency or previous allergic reaction to intravenous immunoglobin (IVIG)/subcutaneous immunoglobin (SCIG)
- •Positive screening test for hepatitis B virus surface antigen, hepatitis C virus antibody, or HIV antibody
- •Positive screening test for rheumatoid factor
- •History of COVID-19
- •Positive FDA-authorized screening test for serum SARS-CoV-2 antibody or presence of SARS-CoV-2 on nasopharyngeal or oropharyngeal swab by FDA-authorized RT-PCR
- •History of allergy, anaphylaxis, or severe reaction to beef products (including milk and gelatin).
结局指标
主要结局
Number of Participants Having Adverse Events
时间窗: 29 Days
Incidence and severity of other adverse events and severe adverse events (SAE)
Number of Participants Having Transfusion-Related Adverse Events
时间窗: 29 Days
transfusion-related adverse events
次要结局
- Pharmacokinetics from screening to day 90(90 Days)
- Number of Participants Having Adverse Events(90 Days)
研究者
研究点 (6)
Loading locations...
相似试验
Unknown
1 期
Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19COVID-19SARS-CoV2NCT04469179SAb Biotherapeutics, Inc.21
已完成
1 期
Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)CoronaVirus Disease-2019 (COVID-19)NCT04644120AbbVie25
已完成
不适用
Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19Covid19NCT04770740Canisius-Wilhelmina Hospital40
Unknown
2 期
Clinical Trial to "Study the Efficacy and Therapeutic Safety of Ivermectin: (SAINTBO)Covid19NCT04836299Universidad Mayor de San Simón90
已完成
3 期
STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19Covid19NCT04817332University of Dundee406